Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Treasury Shares: 2015-2025

Historic Treasury Shares for Seres Therapeutics (MCRB) over the last 9 years, with Sep 2025 value amounting to $100,824.

  • Seres Therapeutics' Treasury Shares fell 96.34% to $100,824 in Q3 2025 from the same period last year, while for Sep 2025 it was $100,824, marking a year-over-year decrease of 96.34%. This contributed to the annual value of $81,459 for FY2024, which is 97.59% down from last year.
  • As of Q3 2025, Seres Therapeutics' Treasury Shares stood at $100,824, which was up 96.93% from $51,199 recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Treasury Shares peaked at $4.2 million during Q1 2023, and registered a low of $51,199 during Q2 2025.
  • Moreover, its 3-year median value for Treasury Shares was $3.4 million (2023), whereas its average is $2.4 million.
  • Per our database at Business Quant, Seres Therapeutics' Treasury Shares surged by 11,203.92% in 2021 and then slumped by 98.66% in 2025.
  • Over the past 5 years, Seres Therapeutics' Treasury Shares (Quarterly) stood at $734,755 in 2021, then spiked by 110.89% to $1.5 million in 2022, then surged by 117.99% to $3.4 million in 2023, then tumbled by 97.59% to $81,459 in 2024, then crashed by 96.34% to $100,824 in 2025.
  • Its Treasury Shares was $100,824 in Q3 2025, compared to $51,199 in Q2 2025 and $76,477 in Q1 2025.